2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompas...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) Vol. 149; no. 1; p. e1
Main Authors: Joglar, José A, Chung, Mina K, Armbruster, Anastasia L, Benjamin, Emelia J, Chyou, Janice Y, Cronin, Edmond M, Deswal, Anita, Eckhardt, Lee L, Goldberger, Zachary D, Gopinathannair, Rakesh, Gorenek, Bulent, Hess, Paul L, Hlatky, Mark, Hogan, Gail, Ibeh, Chinwe, Indik, Julia H, Kido, Kazuhiko, Kusumoto, Fred, Link, Mark S, Linta, Kathleen T, Marcus, Gregory M, McCarthy, Patrick M, Patel, Nimesh, Patton, Kristen K, Perez, Marco V, Piccini, Jonathan P, Russo, Andrea M, Sanders, Prashanthan, Streur, Megan M, Thomas, Kevin L, Times, Sabrina, Tisdale, James E, Valente, Anne Marie, Van Wagoner, David R
Format: Journal Article
Language:English
Published: United States 02.01.2024
Subjects:
American Heart Association
Atrial Fibrillation - diagnosis
Atrial Fibrillation - epidemiology
Atrial Fibrillation - therapy
Cardiology
Humans
Risk Factors
Thromboembolism
United States - epidemiology
United States
coronary artery disease
antiplatelet agents
thromboembolism
atrial flutter
stents
myocardial infarction
exercise
idarucizumab
rivaroxaban
cardioversion
AHA Scientific Statements
atrial fibrillation
percutaneous coronary intervention
acute coronary syndrome
anticoagulants
dabigatran
sleep apnea
obesity
alcohol
anticoagulation agents
heart failure
left atrial appendage occlusion
risk factors
catheter ablation
apixaban
pulmonary vein isolation
stroke
edoxaban
warfarin
surgical ablation
coronary heart disease
hypertension
ISSN:1524-4539, 1524-4539
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" and the "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Instructional Material/Guideline-3
content type line 23
ISSN:1524-4539
1524-4539
DOI:10.1161/CIR.0000000000001193